CN106075450A - 用于树突状细胞癌症疫苗的小分子增强剂 - Google Patents

用于树突状细胞癌症疫苗的小分子增强剂 Download PDF

Info

Publication number
CN106075450A
CN106075450A CN201610493117.7A CN201610493117A CN106075450A CN 106075450 A CN106075450 A CN 106075450A CN 201610493117 A CN201610493117 A CN 201610493117A CN 106075450 A CN106075450 A CN 106075450A
Authority
CN
China
Prior art keywords
tumor
tumors
ari
cancer
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610493117.7A
Other languages
English (en)
Chinese (zh)
Inventor
W.W.巴乔夫钦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of CN106075450A publication Critical patent/CN106075450A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201610493117.7A 2011-11-22 2012-11-15 用于树突状细胞癌症疫苗的小分子增强剂 Pending CN106075450A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161562497P 2011-11-22 2011-11-22
US61/562497 2011-11-22
CN201280067478.5A CN104039952A (zh) 2011-11-22 2012-11-15 用于树突状细胞癌症疫苗的小分子增强剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280067478.5A Division CN104039952A (zh) 2011-11-22 2012-11-15 用于树突状细胞癌症疫苗的小分子增强剂

Publications (1)

Publication Number Publication Date
CN106075450A true CN106075450A (zh) 2016-11-09

Family

ID=48470210

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610493117.7A Pending CN106075450A (zh) 2011-11-22 2012-11-15 用于树突状细胞癌症疫苗的小分子增强剂
CN201280067478.5A Pending CN104039952A (zh) 2011-11-22 2012-11-15 用于树突状细胞癌症疫苗的小分子增强剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280067478.5A Pending CN104039952A (zh) 2011-11-22 2012-11-15 用于树突状细胞癌症疫苗的小分子增强剂

Country Status (9)

Country Link
US (3) US9284337B2 (https=)
EP (2) EP2782994B1 (https=)
JP (2) JP6240083B2 (https=)
CN (2) CN106075450A (https=)
AU (2) AU2012340887A1 (https=)
CA (1) CA2856379A1 (https=)
HK (1) HK1201871A1 (https=)
IL (1) IL232664A0 (https=)
WO (1) WO2013078059A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013078059A1 (en) * 2011-11-22 2013-05-30 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines
JP2018500299A (ja) 2014-11-25 2018-01-11 バイオエクセル コーポレーション 神経線維腫症２型に関連する腫瘍の治療のためのユビキチン−プロテアソーム系阻害剤の使用
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US11000521B2 (en) 2015-08-03 2021-05-11 Institut Pasteur Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
US11583516B2 (en) * 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
WO2018187698A2 (en) * 2017-04-07 2018-10-11 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists
US11559537B2 (en) 2017-04-07 2023-01-24 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
JP2019208422A (ja) * 2018-06-04 2019-12-12 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ヒアルロニダーゼを含む新規な組換えエキソソーム及びその用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010549A1 (en) * 1998-08-21 2000-03-02 Point Therapeutics, Inc. Regulation of substrate activity
WO2000071135A1 (en) * 1999-05-25 2000-11-30 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
WO2007123686A2 (en) * 2006-03-31 2007-11-01 Point Therapeutics, Inc. Dpp inhibitors and uses thereof
US20090124559A1 (en) * 2005-12-19 2009-05-14 Trustees Of Tufts College Office Of Technology And Industry Collaboration Soft Protease Inhibitors and Pro-Soft Forms Thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040145A (en) * 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CN100392074C (zh) * 2003-10-15 2008-06-04 上海海欣生物技术有限公司 树突状细胞肿瘤疫苗及其制法和用途
US7998997B2 (en) * 2005-07-05 2011-08-16 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha
WO2008116054A1 (en) * 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
KR101506751B1 (ko) * 2007-05-17 2015-03-27 디나벡크 가부시키가이샤 수상세포의 제조방법
DK2176408T5 (en) * 2008-01-31 2015-12-14 Curevac Gmbh Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS.
WO2013078059A1 (en) * 2011-11-22 2013-05-30 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010549A1 (en) * 1998-08-21 2000-03-02 Point Therapeutics, Inc. Regulation of substrate activity
WO2000071135A1 (en) * 1999-05-25 2000-11-30 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
US20090124559A1 (en) * 2005-12-19 2009-05-14 Trustees Of Tufts College Office Of Technology And Industry Collaboration Soft Protease Inhibitors and Pro-Soft Forms Thereof
WO2007123686A2 (en) * 2006-03-31 2007-11-01 Point Therapeutics, Inc. Dpp inhibitors and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANGELA PENNISI,ET AL: "Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease", 《BRITISH JOURNAL OF HAEMATOLOGY》 *
JOHN NEMUNAITIS,ET AL: "Pahse I Trial of PT-100(PT-100),A Cytokine-Inducing Small Molecule,Following Chemotherapy for Solid Tumor Malignancy", 《CANCER INVESTIGATION》 *
SHARLENE ADAMS,ET AL: "PT-100,a Small Molecule Dipeptidyl Peptidase Inhibitor,Has Potent Antitumor Effects and Augments Antibody-Mediated Cytotoxicity via a Novel Immune Mechanism", 《CANCER RESEARCH》 *
SIMON J.COUTTS ET AL: "Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. 1. Variation of the P2Position of Xaa-boroPro Dipeptides", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Also Published As

Publication number Publication date
US9839646B2 (en) 2017-12-12
EP2782994A4 (en) 2015-07-15
EP2782994A1 (en) 2014-10-01
JP6240083B2 (ja) 2017-11-29
AU2012340887A1 (en) 2014-07-03
US20140271725A1 (en) 2014-09-18
AU2018204591A1 (en) 2018-07-12
EP2782994B1 (en) 2017-05-10
JP2014533727A (ja) 2014-12-15
CN104039952A (zh) 2014-09-10
US20160310513A1 (en) 2016-10-27
JP2017214420A (ja) 2017-12-07
HK1201871A1 (en) 2015-09-11
US9284337B2 (en) 2016-03-15
US20180092933A1 (en) 2018-04-05
WO2013078059A1 (en) 2013-05-30
EP3106173A1 (en) 2016-12-21
CA2856379A1 (en) 2013-05-30
IL232664A0 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
US9839646B2 (en) Small molecule enhancer for dendritic cell cancer vaccines
US12226480B2 (en) Combination drug including TLR7 agonist
CN111132696B (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
WO2016204193A1 (ja) 抗がん剤
CN110891944B (zh) 用于治疗癌症的化合物、组合物及其用途
US20220313724A1 (en) Compositions for intratumoral administration and related methods
TW202304512A (zh) 雙特異性t細胞銜接體之給藥
HK1229708A (en) Small molecule enhancer for dendritic cell cancer vaccines
HK1229708A1 (en) Small molecule enhancer for dendritic cell cancer vaccines
KR20220004025A (ko) 종양-선택적 병용 요법
WO2025033330A1 (ja) キマーゼ阻害剤と免疫療法の併用による抗腫瘍療法
WO2025021587A1 (en) Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof
HK40034217A (en) Combination drug including tlr7 agonist

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161109

WD01 Invention patent application deemed withdrawn after publication